


# GE Healthcare

## Nomura Inaugural US Industrials Summit

### Pascale Witz

President & CEO, Medical Diagnostics



imagination at work

## Caution Concerning Forward-Looking Statements:

This document contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: current economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices and the value of financial assets; potential market disruptions or other impacts arising in the United States or Europe from developments in the European sovereign debt situation; the impact of conditions in the financial and credit markets on the availability and cost of General Electric Capital Corporation’s (GECC) funding and on our ability to reduce GECC’s asset levels as planned; the impact of conditions in the housing market and unemployment rates on the level of commercial and consumer credit defaults; changes in Japanese consumer behavior that may affect our estimates of liability for excess interest refund claims (Grey Zone); potential financial implications from the Japanese natural disaster; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; the adequacy of our cash flow and earnings and other conditions which may affect our ability to pay our quarterly dividend at the planned level; our ability to convert customer wins (which represent pre-order commitments) into orders; the level of demand and financial performance of the major industries we serve, including, without limitation, air and rail transportation, energy generation, real estate and healthcare; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of financial services regulation; strategic actions, including acquisitions, joint ventures and dispositions and our success in completing announced transactions and integrating acquired businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.


“This document may also contain non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP measures presented in this document, see the accompanying supplemental information posted to the investor relations section of our website at [www.ge.com](http://www.ge.com).”

“Effective January 1, 2011, we reorganized our segments. We have reclassified prior-period amounts to conform to the current-period’s presentation.”

“In this document, “GE” refers to the Industrial businesses of the Company including GECS on an equity basis. “GE (ex. GECS)” and/or “Industrial” refer to GE excluding Financial Services.”

# \$18B broad technology portfolio

## Diagnostic & Clinical Equipment ~46% of revenue



Diagnostic imaging



Clinical products



Home health

\$8.3B

## Information Tech. and Services ~34% of revenues



Clinical and Administrative



Enterprise Imaging



Connectivity & knowledge solutions




Equipment service solutions

\$6.1B

## Molecular Medicine ~20% of revenues




Bio-process



Protein & cell sciences



Contrast media



Molecular pathology

\$3.7B


# Demographic trends escalating demand

## Populations aging

- 2030: the number of people over 65 will
  - Increase 140% in developing world
  - Increase 51% in developed world
- 48.6% relative lifetime healthcare expenditure is expended after age 65


## ...and demand is growing

- Global number of Alzheimer's patients will grow from 36 million in 2009 to 66 million in 2030 and 115 million in 2050
- Global number of cancer patients is predicted to grow from 10.1 million in 2000 to 15.7 million in 2020
- US: chronic disease up 80% and spending up 260% over last 20 years. Spend to increase 2.5X by 2023



Healthcare expenditures outpacing GDP growth

# GEHC- Enables Personalized Medicine



Personalized  
medicine multiple  
components-

GE Healthcare makes it  
happen TODAY

# Radiology & pathology - enablers of personalized medicine



GP



Radiologist

Pathologist

Oncologist



Image-guided biopsies



Screening

Imaging


Biopsy analysis

Treatment decision and monitoring


Suspicion of cancer, more tests needed  
 Radiology imaging for mass confirmation, location  
 Therapy selection limited

Definitive diagnostic... tissue-based today  
 Advanced radiology... activity, molecular  
 Enables specific therapy selection

# GE continues to lead the integration of diagnostic solutions




# Better companion diagnostics needed for Rx development





# Alzheimer's Disease ...


... an unmet need for complete Dx solution



## Enabling First Generation of Disease Modifying Drugs

The imaging agents described are not approved for use by the FDA or any other health regulatory agency


# Medical Diagnostics - Broad range of technologies with prominent global presence



Leader in in-vivo imaging



Clariant – molecular Dx & Pharma R&D hub



Proprietary technology for R&D and clinical use



Innovative digital solutions for pharma and clinical labs

>53,000 GEHC employees with WW infrastructure

Personalized medicine is the next revolution in patient care and GE Healthcare, Medical Diagnostics is leading the way...